Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $47.46 Consensus Target Price from Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned an average recommendation of “Buy” from the fifteen research firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, twelve have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $47.46.

A number of equities research analysts recently weighed in on DYN shares. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 17th. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. JPMorgan Chase & Co. cut their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, March 21st. Royal Bank of Canada restated an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Finally, Chardan Capital reiterated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 17th.

Insider Buying and Selling

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 6,237 shares of company stock valued at $77,760 over the last three months. 20.77% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of large investors have recently made changes to their positions in DYN. GF Fund Management CO. LTD. purchased a new stake in Dyne Therapeutics in the fourth quarter worth $50,000. KBC Group NV lifted its position in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the period. Arizona State Retirement System boosted its stake in shares of Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company’s stock valued at $183,000 after purchasing an additional 1,481 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Dyne Therapeutics by 22.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,247 shares of the company’s stock valued at $201,000 after buying an additional 3,496 shares during the period. Finally, Summit Investment Advisors Inc. raised its stake in Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after buying an additional 721 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $11.32 on Friday. The company has a market capitalization of $1.29 billion, a PE ratio of -3.18 and a beta of 1.19. Dyne Therapeutics has a 52-week low of $6.36 and a 52-week high of $47.45. The business’s fifty day moving average is $10.38 and its 200 day moving average is $18.32.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, sell-side analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.